Compare Bristol-Myers Squibb Co (BMY) vs ProShares Ultra Bloomberg Natural Gas ETF (BOIL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs ProShares Ultra Bloomberg Natural Gas ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.78 (market cap $129.94B), while ProShares Ultra Bloomberg Natural Gas ETF trades at $20.94. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while ProShares Ultra Bloomberg Natural Gas ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, ProShares Ultra Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| BMY | BOIL | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $65.89 | $87.24 |
52-Week Low | $42.60 | $18.74 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
BOIL trades at $20.91, up 0.97% with a bearish technical signal as moving averages indicate selling pressure. The stock recently underwent a 1:2 split effective May 28, 2026. Natural gas market volatility and weather-driven demand fluctuations create trading opportunities, though financial fundamentals remain undisclosed in current data.
Outlook hinges on natural gas price movements and energy sector dynamics. Investment appeal lies in leveraged exposure to gas futures via the ETF structure, but risks include commodity price swings and lack of traditional corporate fundamentals. Bearish technicals suggest cautious entry points near support at $20.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About ProShares Ultra Bloomberg Natural Gas ETF
BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.
Read more on BOIL →
